TY - JOUR
T1 - Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects
AU - Lee, Candace Y.W.
AU - Chen, Horng H.
AU - Lisy, Ondrej
AU - Swan, Suzanne
AU - Cannon, Courtney
AU - Lieu, Hsiao D.
AU - Burnett, John C.
PY - 2009/6
Y1 - 2009/6
N2 - CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.
AB - CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.
KW - C-type natriuretic peptide
KW - CD-NP
KW - Chimeric natriuretic peptide
KW - Dendroaspis natriuretic peptide
UR - http://www.scopus.com/inward/record.url?scp=67149084605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67149084605&partnerID=8YFLogxK
U2 - 10.1177/0091270009336233
DO - 10.1177/0091270009336233
M3 - Article
C2 - 19395584
AN - SCOPUS:67149084605
SN - 0091-2700
VL - 49
SP - 668
EP - 673
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
IS - 6
ER -